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Background: Attention for Evidence Based Medicine (EBM) is growing, but evidence for orphan drugs is argued to
be limited and inferior. This study systematically reviews the available evidence on clinical effectiveness, cost-
effectiveness and budget impact for orphan drugs.
Methods: A systematic review was performed in PubMed, Embase, NHS EED and HTA databases for 11 inpatient
orphan drugs listed on the Dutch policy rule on orphan drugs. For included studies, we determined the type of
study and various study characteristics.
Results: A total of 338 studies met all inclusion criteria. Almost all studies (96%) focused on clinical effectiveness of
the drug. Of these studies, most studies were case studies (41%) or observational studies (39%). However, for all
orphan diseases at least one experimental or quasi-experimental study was found, and a randomized clinical trial
was available for 60% of the orphan drugs. Eight studies described the cost-effectiveness of an orphan drug; an
equal number described an orphan drug’s budget impact.
Conclusions: Despite the often heard claim that RCTs are not feasible for orphan drugs, we found that an RCT was
available in 60% of orphan drugs investigated. Cost-effectiveness and budget impact analyses for orphan drugs are
seldom published.
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Evidence based medicine (EBM) stresses the importance
of evidence stemming from clinical studies next to clin-
ical experience, rather than making treatment decisions
on intuition and clinical experience alone [1]. Attention
for EBM in reimbursement decisions on drugs has grown
over the years, also for policy decisions concerning drugs
for rare diseases (i.e. orphan drugs). Compared to the evi-
dence base for common drugs, however, the available evi-
dence on effectiveness, cost-effectiveness and budget
impact of most orphan drugs is limited. The evidence that
is available, often does not meet traditional quality stan-
dards. Small number of patients and heterogeneity of the
diseases hampers enrollment of sufficient patients in trials
[2,3]. Randomized controlled trials (RCTs) are therefore
often claimed to be unsuitable for orphan diseases [4,5]* Correspondence: kanters@bmg.eur.nl
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reproduction in any medium, provided the orand thus inferior evidence is deemed satisfactory by deci-
sion makers [6,7].
In the Netherlands, from 2006 till 2012 a policy rule
enabled temporary reimbursement for orphan drugs. For
these drugs, treatment centers are required to collect
data on effectiveness and cost-effectiveness over a period
of 4 years. The Dutch policy rule on orphan drugs lists
11 inpatient therapies for 10 orphan diseases (Table 1);
two therapies are listed on the policy rule for one indica-
tion (Fabry disease). Table 1 also provides the number of
patients deemed eligible for treatment in the Netherlands
as well as the estimated costs per patient and total budget
impact of the treatment and the year for which these fig-
ures were estimated. Finally, Table 1 provides information
about whether the EMA provided marketing authorization
under exceptional circumstances (i.e. authorization was
granted despite an incomplete dossier with respect to
safety and/or efficacy). These estimates were based on the
Dutch temporary reimbursement dossiers.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Orphan drugs and indications on the Dutch policy rule
Indication Treatment Prevalence
(100,000
live births)*
Estimated annual
costs / patient
in € **
Dutch budget
impact in € **
Year costs
were assessed
Exceptional
circumstances
authorization
Acute Lymphoid Leukemia (ALL)
in children
Clofarabine (Evoltra) 8.1 54 K 0.7 M 2007 Yes
Cryopyrin Associated Periodic
Syndromes (CAPS)
Canakinumab (Ilaris) 0.10 *** 66 K 2.6 M 2010 Yes
Chronic Lymphoid Leukemia
(CLL) in patients refractory to
fludarabine and alemzumab
Ofatumumab (Arzerra) 30 39 K 1.0 M 2011 No
Fabry disease Agalsidase α (Replagal) 30 199 K 3.2 M 2009 Yes
Fabry disease Agalsidase β (Fabrazyme) 30 194 K 5.7 M 2009 No
Mucopolysaccharidosis I (MPSI) Laronidase (Aldurazyme) 1.3 300 K 7.5 M 2003 Yes
Mucopolysaccharidosis II (MPSII) Idursulfase (Elaprase) 0.6 600 K 9.6 M 2007 Yes
Mucopolysaccharidosis VI (MPSVI) Galsulfase (Naglazyme) 0.16 600 K 4.2 M 2007 Yes
Paroxysmal Nocturnal
Hemoglobinuria (PNH)
Eculizumab (Soliris) 0.8 358 K 10.6 M ***** 2008-2010 No
Pompe disease Alglucosidase alfa
(Myozyme)
1.5 38 K; 382 K **** 31.0 M 2007 No
Soft Tissue Sarcoma (STS) Trabectedin (Yondelis) 23.7 22 K 5.3 M 2010 Yes
* European estimates obtained from Orphanet [8]; ** Obtained from CFH (accessible through www.cvz.nl, in Dutch); *** U.S. estimate [9]; **** Costs for infantile
patients are estimated at €38 K, and costs for adults are estimated at €382 K ***** Average estimated yearly budget impact for the period 2008-2010.
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ness, cost-effectiveness and budget impact is available
for these drugs. For this purpose, a systematic review
was conducted. The findings of this review provide
insight into what type of studies (with respect to study
design) were performed in orphan diseases despite small
numbers of patients.
Methods
Search strategy
The PRISMA guidelines for systematic reviews were
followed [10]. A literature search was conducted in
PubMed and Embase for all orphan drugs on the policy
rule. The literature searches were performed in August
2012. The search terms included the disease and treatment
(brand name and generic name; Table 1). For instance the
following search string was performed for acute lymphoid
leukemia: Acute Lymphoid Leukemia [OR] Acute Lymph-
atic Leukemia [AND] Clofarabine [OR] Evoltra. Similar
search strings were used for the other orphan drugs. In
both PubMed and Embase, the search was limited to Eng-
lish results. No additional search terms or limitations were
used to ensure all relevant studies were found. A supple-
mentary search was performed in the NHS Economic
Evaluation Database (NHS EED) and HTA database to
identify literature on cost-effectiveness (both databases
were accessed through http://www.crd.york.ac.uk/CRD
Web/HomePage.asp). Only treatment (brand name and
generic name) was used as a search term. The searches in
the grey literature were performed in September 2012.Study selection
Eligibility criteria were stated before assessment of the
studies. Two researchers (TK & CdS) subsequently de-
cided independently on selection of the studies. In the
first selection round, studies from PubMed and Embase
were screened on the basis of titles and abstracts. In a
consensus meeting differences were discussed. The
same reviewers then assessed the full-text articles of the
remaining studies. Studies from grey literature were
assessed in the same way.
The following eligibility criteria were used for all drugs
investigated (in this order):
1. Relevance to disease of interest: only studies on the
disease of interest were included (e.g. exclude studies
on the treatment of other diseases, orphan diseases
in general, etc.)
2. Primary focus on disease of interest: only studies
focusing primarily on the disease of interest were
included (e.g. exclude studies on multiple diseases
one of which is the disease of interest)
3. Treatment: only studies on the effectiveness, cost-
effectiveness and budget impact of the treatment of
interest were included (e.g. exclude studies on
alternative treatment options)
4. Treatment of humans: only studies on the treatment
of humans were included
5. Format: only research articles were included (e.g.
exclude conference proceedings, editorials, comments,
letters, conference abstracts, supplements etc.)
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included (e.g. exclude summaries and reviews)
7. Duplicates: Multiple publications on the same study
were identified in the assessment of full-texts. These
studies were included in the analyses only once, to
avoid double counting.
8. Accessibility: papers for which no abstract and no
full-text were available were excluded.
For Acute Lymphoid Leukemia (ALL) and Chronic
Lymphoid Leukemia (CLL), additional exclusion criteria
were defined. When reviewing the evidence for ALL,
studies in adult patient populations were excluded, as
the treatment is only registered for the use in children
and adolescents in the Netherlands. For CLL, only stud-
ies on patients who were refractory to fludarabine and
alemtuzumab were included; studies on ofatumumab in
previously untreated patients were also excluded to
comply with the Dutch indication for of atumumab.
When the drug was provided as part of a combination
therapy, the record was excluded on account of the
third exclusion criterion (i.e. the focus was not on the
treatment of interest).
Analyses of included studies
Two researchers (TK and CdS) carried out the data ex-
traction independently. Included studies were classified
into three groups with respect to subject: 1) effectiveness;
2) budget impact; 3) cost-effectiveness. Studies could po-
tentially be classified into more than one group.
Studies on clinical effectiveness were examined using
the hierarchical level of the study design [11]. Interven-
tional studies (experimental or quasi-experimental de-
signs) were defined as studies in which the investigator
determined treatment regimen. In contrast, in observa-
tional studies treatment was decided on the basis of clin-
ical characteristics of individual patients. Studies were
labeled case studies when patients were individually de-
scribed. Extension studies of clinical trials were consid-
ered as observational studies when all patients were
treated with the new drug.
In addition, several key elements of study design were
identified: control, randomization, blinding, follow-up
duration and number of patients enrolled in the study.
Controls, if any, could be placebo, historical, healthy and
untreated patients or patients receiving supportive care.
Randomization could have been done with respect to treat-
ment, dosage, route of administration or no randomization.
Blinding options were double blind, investigator blind,
patient blind or open label. For interventional studies the
follow-up duration of the study was also assessed.
Articles were considered as describing budget impact
when total costs on a societal or health care level were
provided; the sole mention of treatment cost per patientswas not considered as a budget impact analysis. The re-
lationship between disease prevalence and available evi-
dence was tested using a Spearman correlation.
Results
Figure 1 shows that Embase yielded the most results from
the literature. Searches in grey health economic literature
resulted through the HTA and NHS EED databases in an-
other 44 studies. After removal of duplicates, 3,612 unique
studies remained. A total of 2,062 studies were excluded
after screening titles and abstracts. Consequently, 1,550
(42.9% of total studies assessed) full-text articles were
assessed, of which 338 met the inclusion criteria. More
than one third of the 1,550 articles (39.4%) were excluded
on the basis of format and a similar number (37.5%) was
excluded due to being summary articles.
Table 2 shows that almost all of the 338 included stud-
ies described effectiveness of therapy. Only eight studies
focused on cost-effectiveness, two of which were found
in published papers and six in the grey literature (i.e.
reports from various national health technology assess-
ment agencies). Eight studies described the budget im-
pact of an orphan drug. Budget impact for agalsidase α
and agalsidase β was described in the same article. Six
reports from the grey literature described both cost-
effectiveness and budget impact of an orphan drug.
Effectiveness
Case studies made up the largest share (42%) of all stud-
ies on effectiveness (see Tables 3 and 4). A further 39%
included studies described observational studies. Al-
though only a limited number of interventional studies
were described (in total 19%), Table 3 shows that inter-
ventional studies were available for all drugs. For most
interventional studies, study designs were adapted, par-
ticularly with respect to use of a placebo control group
and blinding. Only a minor share of interventional
studies (n = 14; 22%) involved a randomized, placebo-
controlled, double blinded clinical trial. For four orphan
drugs, no such study was available.
In 33% of the interventional studies and 28% of the
observational studies a control group was used. In most
studies healthy controls and historical controls were
used as a comparison group; in only 21% (12/58) of the
studies the control group received placebo treatment.
Interventional studies often applied multicenter and
international study designs to enlarge sample sizes. Never-
theless, the size of the study population in these interven-
tional studies averaged 48 patients (range 7-270). A total
of 16% of observational studies (21/132) were based on
registry data; the majority stemming from the registry set
up for agalsidase α in Fabry disease.
No significant correlation was found between the dis-
ease prevalence and the number of included studies on
1,121 PubMed records 3,286 Embase records
3,612 records after duplicates 
removed
3,612 titles and abstracts
screened
2,062 records excluded
1,550 full-text articles assessed 
for eligibility
1212 full-text articles excluded
2 disease of interest
7 disease focus
131 treatment of interest
18 treatment humans
477 format
455 summaries
41 double
81 access
338 records included in
systematic review
44 HTA and NHS EED records
Figure 1 Flow chart of inclusion of studies.
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be fewer studies available for orphan drugs with market
authorization under exceptional circumstances compared
to drugs authorized without exceptional circumstances
(average 25 versus 36 studies, respectively). However, the
limited number of drugs under study limited the statistical
power to detect any important differences.Table 2 Subject of included articles
Included
studies
Effectiveness Cost-
effectiveness
Budget
impact
ALL 8 7 1 1
CAPS 7 7 0 0
CLL 3 2 1 0
Fabry
(agalsidase α)
65 63 0 2
Fabry
(agalsidase β)
66 64 1 1
MPSI 26 26 0 0
MPSII 22 21 1 1
MPSVI 24 24 0 0
PNH 23 21 1 2
Pompe 53 53 0 0
STS 41 38 3 1
Total 338 326 8 8
Six studies described both cost-effectiveness and budget impact; Six studies
were included both for agalsidase α and agalsidase β; Six studies were
included for multiple MPS diseases; In ten articles (one for CAPS; four for Fabry
(α); one for Fabry (β); one for MPSI and three for Pompe) more than one study
was described.Cost-effectiveness analyses and budget impact studies
Only eight studies described a cost-effectiveness analysis
of an orphan drug. All cost-effectiveness analyses made
use of a health economic model. Seven studies presented
a cost-utility analysis, in which incremental costs per
QALY (quality adjusted life years) ratio was calculated,
whereas one study described a cost per life year gained.
All studies included survival gains in their analyses.
Eight studies described the budget impact of an orphan
drug. Most studies (n = 6) only described the costs of
treatment itself, but the budget impact study on agalsidase
α and agalsidase β as published in the same paper exam-
ined the impact of the interventions on the health care
budget as a whole, including (substitution of) costs of
alternative treatments and other health care usage.
Discussion
This study reviewed the available evidence for 11 orphan
drugs listed on the Dutch policy rule on orphan drugs.
In total, over 3,612 studies on these orphan drugs were
reviewed, of which 3,274 (91%) were excluded; 338 stud-
ies remained. The vast majority of these studies focused
on drug effectiveness. These results resemble the results
of a recent study in oncologic orphan drugs, which also
showed the remarkable absence of pharmaco-economic
evidence in these drugs [7].
A notable finding in this review was that interven-
tional studies were available for all of the 11 orphan
treatments investigated. In fact, a placebo-controlled
double blind randomized trial was available for seven of
Table 3 Study characteristics of interventional studies
Number (% of
all effectiveness
studies)
Control
group
Random-ization Open
label
RCT* Single
center
International Mean follow-up duration
in weeks [min-max]
Mean number of
patients [min-max]
ALL 2 (29%) 0 0 2 0 1 0 Unknown 39 [17-61]
CAPS 2 (22%) 1 1 1 1 0 2 64 [24-104] 99 [31-166]
CLL 2 (100%) 0 0 2 0 0 2 78 [52-104] 86 [33-138]
Fabry (α) 15 (22%) 8 8 7 6 4 5 35 [10-104] 26 [10-80]
Fabry (β) 10 (16%) 4 3 8 2 2 5 85 [20-234] 50 [13-134]
MPSI 3 (12%) 2 2 2 1 0 3 35 [26-52] 33 [20-45]
MPSII 3 (14%) 2 2 1 2 0 1 44 [26-53] 39 [10-96]
MPSVI 3 (13%) 0 1 2 0 0 2 95 [48-190] 8 [7-10]
PNH 4 (19%) 1 1 3 1 1 2 26 [12-52] 56 [11-97]
Pompe 8 (14%) 3 2 7 1 3 4 70 [26-120] 23 [5-90]
STS 12 (32%) 0 1 12 0 0 6 42 [9-104] 64 [13-270]
Total 64 (19%) 21 21 47 14 11 32 57 [9-234] 48 [7-270]
*RCT = Placebo controlled, randomized, double-blind, clinical trial.
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of two earlier studies examining EMA drug approval
dossiers, which found that about 60% of orphan drugs
were assessed using an RCT [12,13]. While this seems to
contrast with the claim that randomized controlled trials
are not feasible for orphan drugs [4,5], the current re-
view also showed that the design of these trials differed
compared to ordinary RCTs, with a particular focus on
multi-center, international studies. Earlier studies com-
paring orphan and non-orphan cancer and neurological
drugs also showed adaptations in study design in orphan
drug studies [14,15]. Studies in various therapeutic areas
have shown that the size of study population seen in or-
phan drug RCTs is also significantly smaller than those
for non-orphan drugs [14,16].Table 4 Study characteristics of observational studies and cas
Observational studies
Number (% of all
effectiveness studies)
Control group Single center
ALL 1 (14%) 0 0
CAPS 5 (56%) 3 2
CLL 0 (0%) - -
Fabry (α) 37 (55%) 10 17
Fabry (β) 29 (45%) 13 18
MPSI 7 (27%) 0 5
MPSII 9 (41%) 1 3
MPSVI 5 (21%) 0 1
PNH 8 (38%) 5 0
Pompe 14 (25%) 2 4
STS 17 (45%) 3 8
Total 132 (39%) 37 58An adequate study design in studies assessing orphan
drugs is not only important because enlisting patients in
badly designed studies is unethical [17], but also, due to
the small number of patients, there is generally only ‘one
shot to do it right’; no treatment-naïve patients might be
found after an initial study has been performed. Evalu-
ation of the included studies on effectiveness showed
that adaptations to study design were not simply made
because of the small number of patients, but also be-
cause of other aspects. For instance, in the absence of an
alternative treatment it can be considered unethical to
withhold treatment from patients [18]. This was espe-
cially seen as a hurdle against setting up a placebo-
controlled trial for children and infantile patients with
high mortality risks (for instance [19]). In addition, whene studies
Case studies
Registry data Mean number of patients
[min-max]
Number (% of all
effectiveness studies)
0 5 [5] 4 (57%)
0 25 [10-35] 2 (22%)
- - 0 (0%)
13 102 [7-752] 15 (22%)
3 62 [6-822] 25 (39%)
1 141 [5-891] 16 (62%)
3 56 [11-124] 10 (45%)
1 41 [3-132] 16 (67%)
0 58 [6-187] 9 (43%)
0 26 [8-74] 34 (61%)
0 60 [7-379] 9 (24%)
21 58 [3-891] 140 (42%)
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be difficult to initiate a placebo-controlled trial.
A large part of the studies that were assessed were ob-
servational studies. In reading this review, it must be
considered that observational studies, when adequately
set up and performed, need not always be inferior to
randomized clinical trials or systematically overestimate
treatment effects [11,20]. Although an RCT is the most
appropriate study design to prevent the treatment effect
from being biased, in some cases, RCTs might not be a
feasible method to study effectiveness of therapy [21].
In this sense, for example, problems relating to the
feasibility of blinding or randomization, and ethical con-
siderations also determine whether an RCT is the most
suitable study design.
A large share (38%) of full-text publications were
excluded because they only provided a summary of
available evidence and did not contribute any new
knowledge on the particular orphan drug. This high fre-
quency of summaries might be explained by the orphan
status of the diseases. Due to the rarity of the diseases,
most clinicians might encounter only one or two pa-
tients with a particular orphan disease during their ca-
reers [22]. This can lead to delays in diagnoses and even
misdiagnosis [23,24]. To educate other clinicians about
the disease, experts on particular orphan diseases might
frequently summarize the current state of knowledge in
summary articles. Any delay in making the right diagno-
sis is unwanted, especially because for some orphan dis-
eases effectiveness of treatment is dependent on timely
initiation [25-28]. In addition, a substantial proportion
of studies assessed (39%), was excluded because these
were not classified as research articles, but had another
format (predominantly conference abstracts). In this
sense, conference presentations are also hypothesized to
be used to disseminate knowledge to other physicians
about new therapies and educate other clinicians about
orphan diseases.
Limitations of the study
As with any systematic review, the existence of a publica-
tion bias cannot be ruled out – studies without significant
therapeutic effects may not be published. Publication bias
might especially be prominent for cost-effectiveness ana-
lyses. Because of high costs, orphan drugs are rarely cost-
effective under conventional thresholds [29] and this
might decrease pharmaceutical companies’ incentives to
publish such analyses. Publications describing budget im-
pact might be less prone to publication bias, since budget
impact is generally small for an orphan drug due to the
small numbers of patients treated. However, for all orphan
drugs combined, the budget impact is substantial [30]. A
publication bias for budget impact analyses can therefore
not be ruled out.The Dutch policy rule was specifically designed to pro-
vide early access to high-priced orphan drugs (with an
expected budget impact of at least €600,000) for diseases
with high unmet medical need. The drugs listed on the
policy rule might not be representative for other orphan
drugs, which might limit the generalizability of our
results to other orphan drugs. Furthermore, transfer-
ability of the findings for these drugs to outpatient
drugs needs to be studied in future research. However,
this review covered 11 inpatient orphan drugs from a
broad spectrum of disease areas. The overall conclu-
sions could therefore be considered to represent the
situation with orphan drugs in general, and not simply
the situation with a specific disease.
Implications
In assessing the effectiveness of orphan drugs, policy
makers can expect an international interventional study
to be available. However, policy makers should not ex-
pect that country-specific RCTs have been carried out.
In assessing the cost-effectiveness and budget impact of
treatments, policy makers should not expect to find large
body of evidence in the literature. Instead, they are re-
stricted to evidence submitted by pharmaceutical compan-
ies or to coverage-with-evidence-development schemes.
Whether the available evidence is considered to be
sufficient fully depends on the role of evidence based
medicine in reimbursement decisions. Further research
is needed to examine the relation between available evi-
dence and positive reimbursement decisions.
Conclusions
The results of this review showed that at least one inter-
ventional study was conducted for all orphan drugs and
that at least one randomized placebo-controlled, double-
blind, clinical trial was available for over 60% of orphan
drugs. The claim that RCTs are not feasible in orphan dis-
eases therefore does not seem to hold for all orphan dis-
eases. Cost-effectiveness and budget impact analyses for
orphan drugs are seldom published.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TK performed the literature searches. TK and CdS performed the inclusion
and exclusion of studies. All authors were involved in the design of the
study and have been involved in writing and revising the manuscript. All
authors have given final approval of the final version of the manuscript.
Acknowledgements
This study was financially supported by the Netherlands Organization for
Health Research and Development (ZonMw; grant no. 152002045). The
funding source had no role in the design, analyses, reporting of the study or
in the decision to submit the manuscript for publication.
Received: 16 May 2013 Accepted: 9 August 2013
Published: 16 August 2013
Kanters et al. Orphanet Journal of Rare Diseases 2013, 8:124 Page 7 of 7
http://www.ojrd.com/content/8/1/124References
1. Sackett DL, Rosenberg WM, Gray J, Haynes RB, Richardson WS: Evidence
based medicine: what it is and what it isn't. BMJ 1996, 312:71–72.
2. Buckley BM: Clinical trials of orphan medicines. Lancet 2008, 371:2051–2055.
3. Luisetti M, Balfour-Lynn IM, Johnson SR, Miravitlles M, Strange C, Trapnell
BC, Van Bronswijk H, Vogelmeier C: Perspectives for improving the
evaluation and access of therapies for rare lung diseases in Europe.
Respir Med 2012, 106:759–768.
4. Hughes DA, Tunnage B, Yeo ST: Drugs for exceptionally rare diseases: do
they deserve special status for funding? QJM 2005, 98:829–836.
5. Wilcken B: Rare diseases and the assessment of intervention: what sorts
of clinical trials can we use? J Inherit Metab Dis 2001, 24:291–298.
6. Dupont AG, Van Wilder PB: Access to orphan drugs despite poor quality
of clinical evidence. Br J Clin Pharmacol 2011, 71:488–496.
7. Cheng MM, Ramsey SD, Devine EB, Garrison LP, Bresnahan BW, Veenstra DL:
Systematic review of comparative effectiveness data for oncology
orphan drugs. Am J Manag Care 2012, 18:47–62.
8. Orphanet: Prevalence of rare diseases. Paris: Bibliographic data; 2011.
9. Toker O, Hashkes PJ: Critical appraisal of canakinumab in the treatment of
adults and children with cryopyrin-associated periodic syndrome (CAPS).
Biologics 2010, 4:131–138.
10. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. Ann Intern
Med 2009, 151:264–269.
11. Concato J, Shah N, Horwitz RI: Randomized, controlled trials,
observational studies, and the hierarchy of research designs. N Engl J
Med. 2000, 342:1887–1892.
12. Joppi R, Bertele’ V, Garattini S: Orphan drugs, orphan diseases. The first
decade of orphan drug legislation in the EU. Eur J Clin Pharmacol 2012,
69:1006–1024.
13. Putzeist M, Heemstra HE, Garcia JL, Mantel-Teeuwisse AK, Gispen-De Wied
CC, Hoes AW, Leufkens HG: Determinants for successful marketing
authorisation of orphan medicinal products in the EU. Drug Discov Today
2012, 17:352–358.
14. Kesselheim AS, Myers JA, Avorn J: Characteristics of clinical trials to
support approval of orphan vs nonorphan drugs for cancer. JAMA 2011,
305:2320–2326.
15. Mitsumoto J, Dorsey ER, Beck CA, Kieburtz K, Griggs RC: Pivotal studies of
orphan drugs approved for neurological diseases. Ann Neurol 2009,
66:184–190.
16. Orfali M, Feldman L, Bhattacharjee V, Harkins P, Kadam S, Lo C, Ravi M,
Shringarpure D, Mardekian J, Cassino C, Coté T: Raising orphans: how
clinical development programs of drugs for rare and common diseases
are different. Clin Pharmacol Ther 2012, 92:262–264.
17. Halpern SD, Karlawish JH, Berlin JA: The continuing unethical conduct of
underpowered clinical trials. JAMA 2002, 288:358–362.
18. Rothman KJ, Michels KB: The continuing unethical use of placebo
controls. N Engl J Med 1994, 331:394–398.
19. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N,
Levine J, Spencer C, McDonald M: Recombinant human acid α-
glucosidase: major clinical benefits in infantile-onset Pompe disease.
Neurology 2007, 68:99–109.
20. Benson K, Hartz AJ: A comparison of observational studies and
randomized, controlled trials. N Engl J Med 2000, 342:1878–1886.
21. Black N: Why we need observational studies to evaluate the
effectiveness of health care. BMJ 1996, 312:1215–1218.
22. Luisetti M, Campo I, Scabini R, Zorzetto M, Kadija Z, Mariani F, Ferrarotti I:
The problems of clinical trials and registries in rare diseases. Respir Med
2010, 104:S42–S44.
23. Stolk P, Willemen MJC, Leufkens HGM: Rare essentials: drugs for rare
diseases as essential medicines. Bull World Health Organ 2006, 84:745–751.
24. Rinaldi A: Adopting an orphan. EMBO Rep 2005, 6:507–510.
25. Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport
DM, Berger KI, Sidman M, Kakkis ED: Long-term efficacy and safety of
laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009,
123:229–240.
26. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M,
Finkel R, Packman S, Bichet DG, Warnock DG: Agalsidase-beta therapy for
advanced Fabry disease. Ann Intern Med 2007, 146:77–86.
27. Van den Hout JMP, Kamphoven JHJ, Winkel LPF, Arts WFM, De Klerk JBC,
Loonen MCB, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W,Van Hirtum H, Van Diggelen OP, Boer M, Kroos MA, Van Doorn PA, Sibbles
B, Van Corven EJJM, Brakenhoff JPJ, Van Hove J, Smeitink JAM, De Jong G,
Reuser AJJ, Van der Ploeg AT: Long-term intravenous treatment of Pompe
disease with recombinant human α-glucosidase from milk.
Pediatrics 2004, 113:e448–e457.
28. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N,
Meldgaard Lund A, Malm G, Van der Ploeg AT, Zeman J:
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and
recommendations for treatment in the era of enzyme replacement
therapy. Eur J Pediatr 2008, 167:267–277.
29. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J: Assessing the
economic challenges posed by orphan drugs. Int J Technol Assess Health
Care 2007, 23:36–42.
30. Schey C, Milanova T, Hutchings A: Estimating the budget impact of
orphan medicines in Europe: 2010-2020. Orphanet J Rare Dis 2011, 6:62.
doi:10.1186/1750-1172-8-124
Cite this article as: Kanters et al.: Systematic review of available
evidence on 11 high-priced inpatient orphan drugs. Orphanet Journal of
Rare Diseases 2013 8:124.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
